GoKawiilRetatrutide trial shows 25% weight loss and eases knee pain, sleep apnea
Late-stage clinical trial results published in the New England Journal of Medicine show patients on the highest dose of retatrutide lost an average of 25% of body weight after 80 weeks, rising to 30% after 104 weeks. More than a third of participants lost 30% or more of their weight, and the drug also improved knee osteoarthritis pain, sleep apnea symptoms, and cardiometabolic markers including blood pressure and cholesterol.
GoKawiil's interpretation of the reporting above, not reported fact.
The results suggest retatrutide could surpass existing GLP-1 drugs like semaglutide and tirzepatide in effectiveness, potentially reshaping the obesity-treatment market. The benefits seen across related conditions such as osteoarthritis and sleep apnea indicate the drug's effects may extend well beyond weight loss alone, though longer-term safety and real-world data will still be needed before approval.
- Highest-dose retatrutide patients lost an average of 30% of body weight after 104 weeks
- The drug improved knee osteoarthritis pain, sleep apnea severity, and cardiometabolic health markers
- Trial included 2,339 participants across 131 sites in 11 countries, with results published in NEJM
Source: arstechnica.com, 2026-09-29
Published there as: “Most powerful obesity drug yet: People lost up to 25% of weight in trial”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.